Accurate HER2 testing of breast cancer play a decisive role for targeted therapy
HER2, belongs to the Epidermal Growth Factor receptor family, is one of The most vμlnerable oncogene in human tumor. Around 15 – 25% of women with early breast cancer hae a type called HER2-receptor positive disease. Breast carcinoma patients with positive expression of HER2 had higher metastatic rate(P<0.01) and poorer survival rate in 5 years(P<0.01). Fluorescence in situ hybridization (FISH) is the most common method of HER2 testing in the clinical.
Fluorescence in situ hybridization (FISH) technique developed. The technique of hybridization in situ with fluorescence allowed him to identify new recurrent genetic changes that are involved in the appearance of this pathology. FISH technique operation difficult, Clinically, there are nearly 1 / 4 of the patients received inappropriate treatment as inaccurate test results. About 20% to 30% of breast cancer patients is HER2-positive breast cancer. Approximately 25 percent of women with breast cancer will have tumors that produce excessive amounts of HER2 protein. Over signals, stimulate cancer cell proliferation crazy. In breast cancer patient, her2 masculine breast cancer patient's worsened speed often is higher than the negative patient. Patients with HER2-positive breast cancer recurrence and distant metastasis is more likely compared to patients with other. Although HER2 positive breast cancer resistance to some chemotherapy, Biological targeted therapy is an effective treatment for HER2-positive breast cancer. Accurate HER2 testing of breast cancer play a decisive role for targeted therapy. Herceptin has demonstrated unprecedented efficacy in treating both early and advanced (metastatic) HER2 positive breast cancer. The mode of action of Herceptin is unique in that it activates the body's immune system and suppresses HER2 to target and destroy the tumour. If determined that her2 is a masculine gender, should in view of her2 gene marching song proper bead Shan Kangba to the treatment, reduce the recrudescence risk promptly. As research into HER2 therapies continues, similar techniques could be developed for other cancers over-expressing different proteins. Herceptin is currently being evaluated for treatment of HER2-positive stomach cancer through an extensive international clinical trial programme.
U.S. Food and Drug Administration (FDA) on Tuesday announced that it has approved a new test measures HER2 gene amplification in breast cancer patients the strength to decide whether they should be anti-cancer drug Herceptin (trastuzumab Natalizumab). HER2 gene control growth, division and repair of breast cancer cells, and when this leads to over too much HER2 protein signal sent to the cells, growth in the unregulated growth and cancer effects. The overexpression of the gene in approximately 18-30 percent of breast cancer.breast cancer her2 testing http://www.cancer-c.com is a new star of Cancer Rehabilitation Website it will be to provide the latest information about Traditional Chinese Medicine(TCM) Breast cancer treatment lung cancer mesothelioma breast Cancer Rehabilitation info
Processing your request, Please wait....
